Segment Information - Net Revenue and Segment Ebitda (Detail) - USD ($) $ in Millions		12 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		$ 4,828	$ 3,998	$ 3,094
Inter-segment revenue elimination		(17)	(19)	(10)
Impairment charges and gain/(loss) on sale of assets		(31)	(9)	(5)
Equity compensation		(54)	(51)	(48)
Restructuring and other special items	[1]	(55)	(31)	(42)
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	[2]	1	182	(1)
Other income (expense), net	[3]	(28)	(3)	(8)
Non-allocated corporate costs, net		(119)	(87)	(42)
Total unallocated costs		(286)	1	(146)
Softgel and Oral Technologies [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		1,246	1,012	1,062
Segment EBITDA		292	237	257
Biologics [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		2,549	1,928	1,021
Segment EBITDA		798	608	237
Oral and Specialty Drug Delivery [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		650	686	676
Segment EBITDA		192	160	201
Clinical Supply Services [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		400	391	345
Segment EBITDA		110	108	91
Total Catalent sub-total of Segment Reporting [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Segment EBITDA		$ 1,392	$ 1,113	$ 786

[1] Restructuring and other special items for the fiscal year ended June 30, 2021 include transaction and integration costs associated with the Anagni, Italy facility acquisition and the MaSTherCell, Skeletal, Delphi, and Acorda transactions, in addition to restructuring costs associated with the closure of the Company's Clinical Supply Services facility in Bolton, U.K. Restructuring and other special items during the fiscal year ended June 30, 2020 include transaction and integration costs associated with the Company’s cell and gene therapy acquisitions and the disposal of a facility in Australia.

[2] Gain on sale of subsidiary for the fiscal years ended June 30, 2022 and 2021 is affiliated with the sale of the Blow-Fill-Seal Business. Loss on sale of subsidiary for the fiscal year ended June 30, 2020 is affiliated with the disposal of a facility in Australia.

[3] Refer to Note 15, Other expense, net, for details of financing charges and foreign currency translation adjustments recorded within other expense, net.